CISCRP Positions Trial Volunteers as Medical Heroes


By Deborah Borfitz

July 28, 2008 | A public awareness campaign that depicts clinical trial volunteers as medical champions has been shown to improve patient enrollment rates by 38 percent or more in six markets where Eli Lilly recently test-marketed the multimedia program.

So reports Diane Simmons, president and CEO of the Massachusetts-based Center for Information & Study on Clinical Research Participation (CISCRP). The “Everyday Heroes” campaign was co-developed by CISCRP with Fast4wD Ogilvy, the study recruitment arm of international advertising and marketing firm Ogilvy & Mather.

The program -- inclusive of five print ads, four radio spots, and one television spot --shows how people of different ages, races, and occupations can contribute to medical research, says Simmons. A phone number (877-MED-HERO) and website (www.medhero.org), where viewers can learn more about the clinical research process are also provided.

In six markets where Lilly ran the campaign -- in conjunction with standard recruitment ads -- response rates were 38 percent better than in 12 other markets where only the recruitment ads were used, says Simmons. On the second go-round with another trial in the same markets, the response rate more than doubled.

Widespread public distrust of the research process has helped reduce trial participation to abysmal levels across most therapeutic categories. The intent of the Everyday Heroes campaign is to “reposition the way the world looks at [trial] volunteers,” says Simmons. “To really have impact, dissemination of the campaign must be on a national scale with over 120 million impressions per quarter, and that is dependent on contributions from all of the clinical research stakeholders -- pharmaceutical companies, CROs [clinical research organizations], academic medical centers, government agencies, disease advocacy groups, hospitals, community health centers, and individual contributors.”

Education is the “important step before participation,” she continues. To that end, CISCRP has spent the past few years developing general educational brochures and customized versions of the same for African-American and Hispanic populations. Educational DVDs have also been produced, most recently disease-specific ones focused on conditions such as diabetes and cancer.

These educational tools are accessible via the CISCRP website, together with “101 facts and figures” about clinical research, says Simmons. The site will soon get a social networking component.

“With all of the information about clinical research that is available online, what the public wants most can be difficult to find,” says Simmons. These findings prompted the development of CISCRP’s free public service (www.SearchClinicalTrials.org). The listing currently pulls from multiple public registries and excludes duplicate entries. “It’s like the Google of clinical trials.” The service has about 250,000 unique users per year, which is expected to grow exponentially to better meet the need for trial volunteers.

The non-profit, founded in 2003 by Kenneth Getz, has already gifted four U.S. cities – Boston, Indianapolis, Dallas, and Philadelphia -- with an annual Aware-for-All Clinical Research Education Day, says Simmons. The event takes place on “neutral turf” and brings together all key stakeholders to raise public awareness of trials while helping professionals in the clinical research enterprise “look at the world through the public’s eyes.”

Invitations to attend come from dozens of organizational partners, such as churches and YMCAs, who CISCRP supplies with educational materials. Based on exit surveys, 75 percent of consumers are more willing to participate in trials after attending the program, says Simmons. “These are not recruitment fairs.” They “put a human face on the people who volunteer for clinical trials while increasing public understanding of the risks and benefits of participating.”

Simmons adds that this form of outreach is needed in many more communities. “It’s time to say ‘thank you’ to the millions of people globally who give the gift of participation each year, and to stay committed to educating, informing, and empowering the public about what it means to be an active participant in the clinical research process.”

Related story:
Is U.S. Patient Recruitment a ‘Losing Proposition’?

________________________________ 

This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.